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OBJECTIVE—Glucagon-like peptide 1 (GLP-1) exerts beneﬁcial
antidiabetic actions via effects on pancreatic - and -cells.
Previous studies have focused on the improvements in -cell
function, while the inhibition of -cell secretion has received less
attention. The aim of this research was to quantify the glucagono-
static contribution to the glucose-lowering effect of GLP-1 infu-
sions in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS—Ten male patients
with well-regulated type 2 diabetes (A1C 6.9  0.8%, age 56  10
years, BMI 31  3 kg/m
2 [means  SD]) were subjected to ﬁve
120-min glucose clamps at fasting plasma glucose (FPG) levels.
On day 1, GLP-1 was infused to stimulate endogenous insulin
release and suppress endogenous glucagon. On days 2–5, pan-
creatic endocrine clamps were performed using somatostatin
infusions of somatostatin and/or selective replacement of insulin
and glucagon; day 2, GLP-1 plus basal insulin and glucagon (no
glucagon suppression or insulin stimulation); day 3, basal insulin
only (glucagon deﬁciency); day 4, basal glucagon and stimulated
insulin; and day 5, stimulated insulin. The basal plasma glucagon
levels were chosen to simulate portal glucagon levels.
RESULTS—Peptide infusions produced the desired hormone
levels. The amount of glucose required to clamp FPG was 24.5 
4.1 (day 1), 0.3  0.2 (day 2), 10.6  1.1 (day 3), 11.5  2.7 (day
4), and 24.5  2.6 g (day 5) (day 2 was lower than days 3 and 4,
which were both similar and lower than days 1 and 5).
CONCLUSIONS—We concluded that insulin stimulation (day 4)
and glucagon inhibition (day 3) contribute equally to the effect of
GLP-1 on glucose turnover in patients with type 2 diabetes, and
these changes explain the glucose-lowering effect of GLP-1 (day
5 vs. day 1). Diabetes 59:1765–1770, 2010
T
he incretin hormone glucagon-like peptide 1
(GLP-1), as well as GLP-1 analogues that are now
being used for the treatment of patients with
type 2 diabetes, potently suppresses -cell secre-
tion (1–4). Despite their hyperglycemia, patients with type
2 diabetes tend to have elevated fasting glucagon levels
and exaggerated glucagon responses to meal ingestion (5).
Since the hyperglucagonemia is thought to contribute to
the hyperglycemia of these patients by increasing hepatic
glucose production (HGP) (6), it follows that the glu-
cagonostatic effect of GLP-1 may be as important clinically
as its insulinotropic effect (7). Glucose-induced inhibition
of -cell secretion may be impaired in type 2 diabetic
patients, but pharmacological amounts of GLP-1 have
been shown to restore -cell sensitivity to glucose (8,9),
and we recently demonstrated that the glucagon-suppres-
sive effect of GLP-1 was similar in patients with type 2
diabetes and healthy control subjects (10).
Thus GLP-1 potently inﬂuences both - and -cell secre-
tion in patients with type 2 diabetes, but the relative roles
of these two effects in relation to the overall glucose-
lowering action of GLP-1 are unclear. In the present
studies, we sought to determine the importance of the
glucagonostatic effect by measuring its contribution to
changes in glucose turnover induced by the infusion of
GLP-1 in pharmacological doses. We employed the pan-
creatic clamp technique (11) using somatostatin to block
the endogenous secretion from the islets while substi-
tuting insulin and/or glucagon levels by infusions de-
signed to mimic either basal levels and/or responses to
a GLP-1 infusion rate (1 pmol/kg/min) known to normal-
ize blood glucose in patients with type 2 diabetes (4). All
examinations were done in the fasting state with plasma
glucose (PG) clamped at individual fasting PG (FPG)
levels. The amount of glucose infused to maintain the
clamp was expected to accurately reﬂect the inﬂuence
of the endocrine perturbations on glucose turnover
(decreased hepatic glucose production and increased
peripheral disposal).
RESEARCH DESIGN AND METHODS
Ten male patients with type 2 diabetes (age 56  10 years, duration of diabetes
6  3 years, BMI 31  3 kg/m
2, waist-to-hip ratio 1.0  0.0, FPG 10.3  2.9
mmol/l [after 1 week of oral antidiabetic drug wash-out], A1C 6.9  0.8%
[during treatment] [means  SD]) were studied. All participants were negative
for both islet cell and GAD-65 autoantibodies, were well-treated with regard to
plasma lipids and blood pressure, and were without overt diabetic complica-
tions. One patient was treated with diet and exercise alone, while the rest
were in oral antidiabetic treatment with metformin (n  4), metformin and
sulfonylurea (n  4), or metformin and sitagliptin (n  1). All patients had an
oral antidiabetic drug wash-out period of 7 days prior to examination, and
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diabetes.diabetesjournals.org DIABETES, VOL. 59, JULY 2010 1765none of the patients were treated with other drugs known to affect the
responses of glucose, insulin, glucagon, or incretin hormones. All subjects
agreed to participate after receiving oral and written information. The
protocol was approved by the Scientiﬁc-Ethical Committee of the Capital
Region of Denmark (registration no. H-C-2007-0072), registered with the
Danish Data Protection Agency (registration no. 2008-41-1809) and Clinical-
Trials.gov (no. 00655603), and performed in accordance with the Helsinki
Declaration II.
Experimental protocol. All patients were investigated in the morning after
an overnight fast (from midnight) on ﬁve separate days. On each day, subjects
received variable infusions for 120 min during which PG was clamped at their
individual FPG level. On day 1, GLP-1 (1.0 pmol/kg/min) was infused to
stimulate endogenous insulin release and suppress endogenous glucagon. On
days 2–5, pancreatic endocrine clamps were performed with the infusion of
somatostatin (450 g/h) and the selective replacement of insulin and/or
glucagon as follows: day 2, GLP-1 plus basal insulin and glucagon (no
glucagon suppression or insulin stimulation); day 3, basal insulin only
(glucagon deﬁciency); day 4, basal glucagon and stimulated insulin; day 5,
stimulated insulin and glucagon deﬁciency. Peptides were infused using
separate infusion pumps from time 0 to 120 min at the following rates: day 2,
GLP-1 (1.0 pmol/kg/min), glucagon (1.25-0.6 ng/kg/min), and insulin (0.1
mU/kg/min); day 3, insulin (0.1 mU/kg/min); day 4, glucagon (1.25-0.6 ng/kg/
min) and insulin (0.2 mU/kg/min [0–60 min], 0.4 mU/kg/min [60–120 min]);
day 5, insulin (0.2 mU/kg/min [0–60 min], 0.4 mU/kg/min [60–120 min]). The
glucagon infusion rate was chosen to give rise to glucagon concentrations
equivalent to the basal levels in the portal vein, while the insulin infusion rates
on days 4 and 5 were designed to mimic the insulin response to GLP-1 on day
1 (Table 1). As the experiments lasted for only 2 h each, we chose not to
substitute growth hormone (12). Each peptide was infused using a separate
infusion pump. Experiments were randomized and performed within 1 week
for each patient. Subjects were investigated in the recumbent position with
one cannula inserted into a cubital vein for infusion of glucose (20%
[weight/volume]) and hormones, and another cannula inserted into the
contralateral cubital vein for the collection of blood samples. This arm was
kept in a heated box (50°C) throughout the experiment to arterialize the
venous blood (13). For bedside PG analyses, blood was collected into ﬂuoride
tubes every 5 min for adjustment of the glucose infusion rate. Additional
samples were drawn at time 15, 10, 0, 15, 30, 45, 60, 75, 90, 105, and 120 min
into iced tubes containing EDTA (6 mmol/l) plus aprotinin (500 kallikrein
inhibitor unit/ml blood) (Trasylol; Bayer, Leverkusen, Germany), and a
speciﬁc dipeptdyl peptidase (DPP)-4 inhibitor (valine-pyrrolidide; 0.01 pmol/l,
ﬁnal concentration) for hormone analyses. Before and after centrifugation
(1,200 g at 4°C for 20 min), tubes were kept on ice; plasma was pipetted to
storage tubes and stored at 20°C until analysis. Serum for insulin and
C-peptide analysis was collected in Z serum clot activator glasses (Greiner
Bio-One, Kremsmu ¨nster, Austria) and left to coagulate for 20 min before
centrifugation and handling as described above. Serum was stored at 80°C
until analysis.
Peptides. Synthetic GLP-1 (7–36) amide (Good Manufacturing Practice
quality, product no. 40061) (PolyPeptide Laboratories, Limhamn, Sweden) and
synthetic somatostatin (GMP quality, product code FP-0467) (PolyPeptide
Laboratories, Torrance, CA) were dissolved in sterilized water containing 2%
human serum albumin and subjected to sterile ﬁltration. The GLP-1 was
demonstrated to be 97% pure and somatostatin 98% pure, and both
peptides were shown to be identical to their natural human counterparts by
high-performance liquid chromatography, mass, and sequence analysis. Ap-
propriate amounts of each peptide for each experimental subject were
dispensed into separate glass ampoules and stored frozen (20°C) under
sterile conditions until the day of the experiment when the solution was
further diluted with saline containing 1% human albumin (Human Albumin;
CSL Behring, Marburg, Germany) (viral safety achieved by procedures spec-
iﬁed in the European Pharmacopoeia). Doses of all hormones were calculated
according to body weight (except for somatostatin, which was given as a ﬁxed
dose [450 g/h]). Insulin (Actrapid; Novo Nordisk, Bagsværd, Denmark) and
glucagon (GlucaGen; Novo Nordisk, Bagsværd, Denmark) were diluted in
saline containing 1% human serum albumin (Human Albumin; CSL Behring,
Marburg, Germany) in saline.
Analyses. PG concentrations were measured during the experiments using a
glucose oxidase method glucose analyzer (Yellow Springs Instrument Model
YSI 2300 STAT plus analyzer; Yellow Springs, OH). Serum insulin and
C-peptide concentrations were measured using two-site assays (electrochemi-
luminescense immunoassay, Roche/Hitachi Modular analytics, Roche Diag-
nostic, Mannheim, Germany). The detection limit for each assay is 2 pmol/l,
and intraassay coefﬁcient of variation are 1.9% (insulin) and 4.6% (C-peptide)
(14). Glucagon and GLP-1 concentrations were measured after extraction of
plasma with 70% ethanol (volume/volume, ﬁnal concentration). The glucagon
radioimmunoassay is directed against the C-terminus of the glucagon mole-
cule (antibody code no. 4305) and therefore mainly measures glucagon of
pancreatic origin. The sensitivity is 	1 pmol/l (15). Total GLP-1 concentra-
tions were determined using antiserum code no. 89390 directed against the
amidated C-terminus of GLP-1. The assay reacts equally with intact GLP-1 and
with GLP-1 (9–36) amide, the primary metabolite (16).
Statistical analyses and calculations. All results are presented as means 
SEM unless otherwise stated. Area under the curve (AUC) was calculated
using the trapezoidal rule with subtraction of baseline values when calculating
incremental/decremental AUCs. Comparisons between the ﬁve different days
were made using two-way ANOVA and Bonferroni post hoc tests. Compari-
sons between speciﬁc days were made using repeated-measures ANOVA with
Tukey post hoc test. P values 0.05 were considered statistically signiﬁcant.
Glucose demands were calculated as the amount of glucose (20% [weight/
volume]) infused (administered by adjustable pump).
RESULTS
Glucose. FPG levels were similar on all ﬁve experimental
days. Mean values for the 120-min clamp period were
10.3  0.05 (day 1), 11.5  0.25 (day 2), 10.2  0.06 (day 3),
10.8  0.11 (day 4), and 10.0  0.1 mmol/l (day 5) with
two-way ANOVA disclosing a slight but signiﬁcant in-
crease in PG on day 2 compared with days 1, 3, and 5 (Fig.
2).
AUCs for PG are given in Table 2. The amounts of
glucose infused in order to maintain the clamp (Table 1
and Fig. 2) were similar on days 1 and 5 (P  not
signiﬁcant [NS]). On day 2, three of the ten patients
required a minimal amount of glucose early in the clamp
(0–30 min) (Fig. 2B). Similar amounts of glucose were
needed on day 3 (representing isolated glucagon inhibi-
tion) and day 4 (representing insulin stimulation) (P 
NS), which, however, were signiﬁcantly (P  0.5) less than
the amounts required on day 1 or day 5.
GLP-1. On days 1 and 2, the GLP-1 infusions resulted in
similar AUCs (Table 2), and no difference between the
curves was observed using two-way ANOVA (P  NS).
Plateau levels of 190  11 and 183  14 pmol/l were
reached within 30 min of starting each infusion (P  NS)
(Fig. 2).
Glucagon. No signiﬁcant differences were found in the
fasting glucagon levels between the ﬁve days (day 1,
TABLE 1
Study design
Basal
insulin
Stimulated
insulin
Glucagon
inhibition
Basal (portal)
glucagon GLP-1
Somatostatin
infusion
Glucose
demand (g)
Day 1 

 
 24.5  4.1
Day 2 

 
 
 0.3  0.2
Day 3 

 
 10.6  1.1
Day 4 

 
 11.5  2.7
Day 5 

 
 24.5  2.6
Data shown are means  SE. Study design and glucose demands for each day.
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0.9; and day 5, 12.7  0.9 pmol/l, P  NS).
A glucagon infusion rate of 1.25 ng/kg/min (n  4) was
calculated to give rise to plasma levels mimicking those in
the portal vein (7) (see below). However, this infusion rate
was individually adjusted in an attempt to maintain PG at
FPG-/clamp-level, thus resulting in actual infusion rates of
1.25 (n  4), 1.0 (n  3), and 0.6 ng/kg/min (n  3).
Despite this, PG increased by 1–2 mmol/l in eight out of ten
patients, therefore the results were combined (Fig. 1C,
Table 2). Assuming minimal hepatic and splanchic deg-
radation, the ratio between portal and peripheral gluca-
gon concentrations (Cportal/Cperipheral) is 1.9 (17).
Therefore we aimed to achieve peripheral plasma glu-
cagon concentrations of 26 pmol/l (fasting glucagon
concentration  1.9). This level was reasonably
matched during the glucagon infusions with glucagon
plateau levels on the two days (days 2 and 4) of 31  4.7
and 31  5.1 pmol/l (P  NS).
Somatostatin proved very efﬁcient in blocking -cell
secretion on both day 3 and day 5 where plasma glucagon
decreased to around 1–2 mmol/l (Fig. 1). A signiﬁcant
inhibition of glucagon was also seen when GLP-1 was
infused (P  0.0001) (Table 2). Toward the end of the
GLP-1 infusion, endogenous glucagon concentrations fell
to levels equal to those on days 3 and 5 (Fig. 1C).
Insulin and C-peptide. As illustrated in Fig. 1D, GLP-1
proved to be highly insulinotropic in all patients result-
ing in a mean plasma insulin plateau of 312  57 pmol/l
and a mean plasma C-peptide plateau of 2.4  0.1 nmol/l
during the ﬁrst 60 min of GLP-1 infusion (15–60 min)
followed by a steady increase in -cell secretion to
maximum values of 722  251 pmol/l (insulin) and 4.5 
0.7 nmol/l (C-peptide) (Fig. 1D and E). On days 2 and 3,
insulin levels remained at basal levels throughout the
120 min clamps (NS vs. day 1). On days 4 and 5, the
insulin infusions successfully mimicked the response to
GLP-1 (day 1) with no signiﬁcant differences according
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FIG. 1. Plasma levels of glucose (A), GLP-1 (B), glucagon (C), insulin (D), and C-peptide (E) during day 1 (F), day 2 (Œ), day 3 (f), day 4 (‚),
and day 5 (E). Data shown are means  SEM. NS indicates P > 0.5.
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Endogenous -cell secretion was strongly inhibited by
somatostatin as evidenced from the C-peptide levels
decreasing equally on days 2–5 (Fig. 1E).
Side effects. Infusion of somatostatin induced a mild,
transient nausea in some of the patients, typically in
combination with glucagon infusion. No other side effects
were observed.
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FIG. 2. Glucose demand (g) for each day: day 1: GLP-1(insulin stimulation, glucagon inhibition); day 2: GLP-1, somatostatin, basal insulin, basal
glucagon; day 3: somatostatin, basal insulin; day 4: somatostatin, “stimulated” insulin (mimicking day 1-insulin response), basal glucagon; day 5:
somatostatin, “stimulated” insulin (mimicking day 1-insulin response). Data shown are means  SEM. A: Glucose demands on each day shown in
grams infused (g); means  SEM. B: Glucose demand calculated from each interval of 30 min on each day. Data shown in grams (g); means  SEM.
NS indicates P > 0.5, *P < 0.5, ***P < 0.001.
TABLE 2
AUC values
Day 1 Day 2 Day 3 Day 4 Day 5
Glucose (mol/l  120 min) 1.4  0.1*
2 1.6  0.1*
1,3,5 1.4  0.1*
2 1.5  0.1 1.4  0.1*
2
GLP-1 (nmol/l  120 min) 20  21 8  1
Glucagon (nmol/l  120 min) 0.9  0.1*
2,4 2  0.5*
1,3,5 1.4  0.1*
2,4 2  0.6*
1,3,5 1.2  0.1*
2,4
Insulin (nmol/l  120 min) 37  11*
2,3 1.1  1*
1,4,5 1.1  1*
1,4,5 25  2*
2,3 24  2*
2,3
C-peptide (nmol/l  120 min) 215  39*
2,3,4,5 56  5*
1 80  7*
1 76  6*
1 82  8*
1
Data shown are means  SE. Differences between the ﬁve days were evaluated for signiﬁcance (P  0.05) using repeated-measures ANOVA
with Tukey post hoc analysis. Glucose is shown as total AUC; GLP-1, glucagon, insulin, and C-peptide as incremental/decremental AUCs.
Signiﬁcant differences are indicated by asterisks (*) followed by the number(s) of the group(s) compared with. Day 1: GLP-1 (insulin
stimulation, glucagon inhibition); day 2: GLP-1, somatostatin, basal insulin, basal glucagon; day 3: somatostatin, basal insulin; day 4:
somatostatin, “stimulated” insulin (mimicking day 1-insulin response), basal glucagon; and day 5: somatostatin, “stimulated” insulin
(mimicking Day 1-insulin response).
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GLP-1 administration has a glucose-lowering effect in
patients with type 2 diabetes (4). The mechanism behind
this antidiabetic effect is dual as GLP-1 both inhibits -cell
secretion and thereby HGP (3) and stimulates -cell secre-
tion leading to insulin-mediated glucose disposal in periph-
eral tissues and additional (insulin-mediated) inhibition of
HGP (3). However in clinical studies it is difﬁcult to
distinguish between the glucose-lowering effect of de-
creased glucagon on one side and the effect of increased
insulin on the other. We decided, therefore, to quantify the
individual contributions of these two glucose-lowering
components by clamping plasma glucose at the preinfu-
sion level (thereby eliminating glucose-induced effects on
glucagon and insulin secretion) and then mimicking the
GLP-1–induced changes in islet hormone secretion using
exogenous insulin and glucagon infusions while simulta-
neously blocking endogenous - and -cell secretion with
somatostatin. Consequently, the amount of glucose re-
quired to maintain the clamp reﬂects the sum of changes in
HGP (although HGP itself was not measured) and periph-
eral disposal of glucose and, thereby represents the net
effect of the endocrine perturbations. Furthermore by
substituting each of the pancreatic hormones separately, it
was possible to determine the individual contributions of
these hormones. Thus, day 1 represented the effects of
GLP-1 alone. On day 2, GLP-1 was again infused but
changes in pancreatic hormone levels were prevented by
means of somatostatin, while basal pancreatic hormone
levels were substituted using insulin and glucagon replace-
ment infusions. On day 3, we examined the effects of
inhibition of glucagon alone, while insulin was kept at
basal levels, and on day 4, glucagon was maintained at
basal (portal) levels, while GLP-1–induced insulin secre-
tion was mimicked by infusion. On day 5, we studied the
effect of mimicking the changes in stimulated insulin and
suppressed glucagon seen in response to GLP-1, but
brought about by somatostatin and insulin infusion (as on
day 4) rather than GLP-1; this served as a control for the
accuracy of the infusion protocols (Figs. 1 and 2).
The infusion protocols appeared successful. Thus soma-
tostatin suppressed glucagon levels to similar low levels as
during GLP-1 infusion, although the suppression occurred
somewhat earlier during somatostatin infusion. Insulin
responses were also well matched (days 4 and 5 vs. day 1)
with similar AUCs (Table 1). For replacement of basal
glucagon levels during somatostatin infusion, we had to
make a choice: either maintain peripheral plasma concen-
trations or try to mimic portal levels, which in the fasting
state have been calculated to exceed peripheral levels by a
factor 1.9 (17), representing the dilution of the splanchnic
circulation into the systemic circulation. Since in humans
the target of glucagon action is the liver (18,19), which is
exposed to portal glucagon levels, we chose the portal
levels; these were successfully reached (in peripheral
plasma) during the glucagon infusions. However, the infu-
sion rate designed for this (1.25 ng/kg/min [7]) resulted in
small and variable increases in PG when given together
with basal insulin replacement. This indicates a slight
overmatching of portal glucagon-to-insulin ratio, presum-
ably reﬂecting that normally portal insulin levels are also
higher than peripheral levels. However because of the
prominent actions of insulin on glucose disposal in periph-
eral tissues, we decided not to attempt to mimic portal
insulin levels. Therefore instead of adjusting insulin infu-
sions, glucagon infusion rates were varied in an attempt to
maintain stable glucose levels. It is clear, however, that the
portal insulin levels are under-matched, both because of
the dilution of the portal into the systemic circulation and
because of the portal insulin uptake. As mentioned, appro-
priately matched infusions would have signiﬁcant effects
on peripheral glucose disposal and furthermore would
have resulted in even higher glucose requirements. This
would indicate the even stronger inﬂuence of glucagon on
glucose turnover. In order to resolve this problem how-
ever further experiments with higher insulin infusion rates
and preferably direct measurements of HGP should be
carried out. The identical glucose requirements do show
that the changes in glucose turnover were similar, and
increasing insulin infusion rates to expected portal levels
during GLP-1 infusion therefore must not result in further
glucose requirements. There are two possible explana-
tions for this conﬂict 1) either the hepatic glucose produc-
tion is already minimal during days 1 and 5 so that further
increases in insulin would not result in signiﬁcant further
decreases in HGP (disregarding the effects on peripheral
glucose disposal), or 2) the slower suppression of gluca-
gon secretion on day 1 compared to day 5 makes up for the
under-matching of portal insulin, resulting in identical
glucose requirements. Possibly, both contribute. From the
present results, we conclude that both inhibition of gluca-
gon and stimulation of insulin secretion are important for
the blood glucose lowering effects of GLP-1, with each
contributing about half of the total effect.
Our ﬁndings suggest that the inhibition of glucagon
secretion is a very important part of the antidiabetic,
glucose-lowering effect of GLP-1. In most clinical studies
of type 2 diabetes treatment with GLP-1 or its analogues
where glucagon levels have been reported, there have
been signiﬁcant reductions both in the fasting state and
after (e.g., meal stimulation), whereas in general, insulin
levels have been less affected (20–24). This should be
considered, however, in light of the often pronounced
reductions in PG levels observed concomitantly. There-
fore, regarding insulin secretion, the effect of GLP-1 seems
to consist of the enhancement of glucose-induced insulin
secretion, resulting in rather unchanged absolute secre-
tion rates, whereas glucagon secretion, which would have
been expected to increase with falling PG levels, actually
decreases. In many patients with type 2 diabetes, both
fasting and postprandial glucagon levels are abnormally
elevated (25–28), possibly due to a decreased ability of
glucose to inhibit glucagon secretion appropriately. The
effects of GLP-1 may, in fact, be viewed as restoration of
the ability of the -cells to react to glucose as was
demonstrated in hyperglycemic clamp studies (8,29). To-
gether, these results support that the inhibition of gluca-
gon secretion by GLP-1 constitutes a very important part
of the glucose-lowering effect of GLP-1, also in the clinical
setting.
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